ADULT COVID-19 2025-2026

The document outlines a federal Request for Proposals (RFP) for adult COVID-19 vaccines, specifically targeting individuals aged 19 and older. It specifies the minimum order size of 100 doses and highlights the federal excise tax of $0.75 per dose. The maximum potential procurement is noted at 10 million doses, with the total cost calculated including the excise tax. This RFP is part of the government's ongoing efforts to ensure vaccine availability for adults, emphasizing the structured approach to procurement to meet public health needs. By clearly delineating the costs and order requirements, the document facilitates the bidding process for suppliers while ensuring compliance with federal guidelines.

The Centers for Disease Control and Prevention (CDC) is soliciting bids for one or more Indefinite Delivery Indefinite Quantity (IDIQ) contracts to purchase U.S.-licensed COVID-19 vaccines for adults. The goal is to leverage Section 317 vaccine purchase funds to obtain vaccines at discounted prices for state and local health departments, particularly for populations at risk of under-vaccination. These contracts enable the CDC to facilitate adult immunization through the National Center for Immunization and Respiratory Diseases (NCIRD). The contract outlines the requirements for vaccine delivery, including minimum shelf life, packaging, and maintenance of FDA-recommended temperatures. Additionally, it details the ordering process via the Vaccine Tracking System (VTrckS) and specifies payment terms, including electronic funds transfer. Contractors must provide advance notice for supply issues and maintain reporting protocols for sales data. The document emphasizes compliance with public health laws, quality standards, and the prohibition of resale of the vaccines obtained under these contracts. It highlights the collaboration between federal, state, and local health entities to ensure effective immunization practices, aiming to achieve higher vaccination coverage among adults.

The Authorized Distributor of Record (ADR) Agreement formalizes the relationship between a supplier and the Centers for Disease Control and Prevention (CDC), designating the CDC as an authorized distributor under the Prescription Drug Marketing Act (PDMA) of 1988 and associated regulations. The agreement requires that the supplier lists all specific products authorized for distribution or confirms that the CDC is designated for the entire product line. The validity of the agreement extends until termination, which can occur with a 90-day notice. It clarifies that the CDC's designation does not provide any rights beyond this ADR status and does not replace any existing or future distribution agreements. Both parties must sign to acknowledge and agree to adhere to these terms. A list of products is to be included as an attachment, specifying details such as product names, dosages, and National Drug Code (NDC) numbers. This document outlines the framework for regulatory compliance and partnership between the supplier and the CDC, pertinent to the distribution of pharmaceuticals and vaccines under federal guidelines.

The Centers for Disease Control and Prevention (CDC) is issuing a Request for Proposals (RFP) for the establishment of Indefinite Delivery Indefinite Quantity (IDIQ) contracts aimed at acquiring U.S.-licensed COVID-19 vaccines for adults. The contracts will utilize Section 317 vaccine purchase funds, allowing purchases below commercial market prices for state and local health departments serving at-risk populations. The awarded vaccines will support adult immunization programs across state health departments, large city programs, and U.S. territories. The contract requires adherence to specific conditions, including a minimum shelf life of 12 months for vaccines and strict temperature controls during transit. Orders will be facilitated through the Vaccine Tracking System (VTrckS), with processes established to ensure fair opportunity for contractors based on clinical appropriateness, local advisory recommendations, and available funding. Key considerations also include restrictions on vaccine use solely for immunization purposes for adults aged 19 and older, and explicit prohibitions against resale or free distribution. The CDC aims to adapt the contracts to future vaccine developments and maintain purchasing parity with commercial markets, ensuring ongoing access to effective COVID-19 vaccinations for public health initiatives.